Retinoic acid receptor alpha; Retinoic acid receptor beta (RAR-α (for Retinoic acid receptor alpha), RAR-β (for Retinoic acid receptor beta))

Retinoic acid receptor alpha and beta are members of the nuclear receptor superfamily, functioning as ligand-activated transcription factors predominantly binding retinoic acid, a derivative of vitamin A[1][4][6]. The proteins consist of a DNA-binding domain, a ligand-binding domain, and a transcriptional activation domain[7]. When activated by binding to their ligands, RAR-α and RAR-β form heterodimers with retinoid X receptors (RXRs) and regulate the transcription of target genes involved in cell growth, differentiation, and embryonic development[1][4][6]. They play central roles in modulating processes such as morphogenesis, organogenesis, cell cycle control, and apoptosis[3][4]. Aberrant RAR signaling, particularly RAR-α, is implicated in diseases such as acute promyelocytic leukemia. Both are considered important therapeutic targets for retinoid-based drug therapies and as biomarkers in oncology[1][4][6][7].

Other names

RAR-alpha (for alpha subtype)RAR-beta (for beta subtype)NR1B1 (for alpha, standard nuclear receptor nomenclature)NR1B2 (for beta, standard nuclear receptor nomenclature)RARA (gene for alpha)RARB (gene for beta)Nuclear receptor subfamily 1, group B, member 1 (for alpha)Nuclear receptor subfamily 1, group B, member 2 (for beta)

Ligand-activated transcriptional regulation: Ligands (like retinoic acid) bind the receptor, triggering conformational changes that recruit or release corepressors and coactivators, modulating gene expression[1][4][6]. Induction of differentiation in leukemic cells (example: use of ATRA in acute promyelocytic leukemia)[1]. Antagonism of RARs blocks retinoid signaling, modulating cellular growth and differentiation.